Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

GENENTECH

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 21, 2025
Income
$50,000.00
Expenses
Not reported
Client
GENENTECH
Filing UUID
5e6ee714-524a-4819-9512-be46eab23501
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 1672- Maintaining Investments in New Innovation Act. Issues related to physician reimbursement for Part B drugs.

Literal federal measure citations: H.R. 1672

HCR · Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

TAX · Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care. Issues related to corporate tax reform.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.